BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Elekta Receives $25 Million Order From China


9/10/2013 7:30:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Elekta Receives USD 25 Million Order from China

BEIJING--(BUSINESS WIRE)-- Regulatory News: The National Health and Family Planning Commission (NHFPC) of the People’s Republic of China announced today that Elekta (EKTAB.ST) has won a major tender for seven Leksell Gamma Knifeâ Perfexion™ units, making it the largest single order of Leksell Gamma Knife systems. The deal has a total value of around USD 25 million.

Elekta was awarded the tender through a central procurement project organized by the NHFPC. Purchasing the Perfexion units is part of the Chinese government’s continuous investment in health care.

With its large unmet need for cancer care and neurological disorders, China continues to grow and is Elekta’s second largest market. Elekta has been present in China since 1982 and is today the market leader with approximately 48 percent of the radiation therapy market share.

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 11:00 CET on September 10, 2013.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

This information was brought to you by Cision http://news.cision.com

Contact:

Johan Andersson

Director, Investor Relations

Elekta AB

Tel: +46 702 100 451

e-mail: johan.andersson@elekta.com

Time zone: CET: Central European Time

or

Håkan Bergström

Chief Financial Officer

Elekta AB Tel: +46 733 342 318

e-mail: haken.bergstrom@elekta.com

Time zone: CET: Central European Time

or

Michelle Joiner

Director

Global Public Relations and Brand Management

Elekta

Tel: +1 770-670-2447

e-mail: michelle.joiner@elekta.com

Time zone: ET: Eastern Time

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Elekta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES